Company profile
Cyclacel Pharmaceuticals, Inc. - Harnessing the cell cycle to treat cancer and other serious diseases
Harnessing the cell cycle to treat cancer and other serious diseases About Cyclacel As a clinical-stage, biopharmaceutical company, we develop innovative ca ...
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
AA | Transaction MzQzMzExMTYzNWFkaXF6a2N4
Published 22 Aug 2024 13:53
CS01 | Transaction MzQzMjkyODQ3MWFkaXF6a2N4
Published 21 Aug 2024 11:07
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Dec 2013 to 30 Nov 2016
Cyclacel has developed a clinical candidate NCE with characteristics enabling the targeting of a previously unexploited mechanism for treatment of oesophageal cancer (OEC), an orphan disease with a high unmet need. This potent and selective PLK1 kinase inhibitor has a strong preclinical rationale for use as a stratified medicine for OEC and other solid tu...
1 Jan 2013 to 31 Dec 2015
Cyclacel has developed a novel clinical candidate NCE affecting previously unexplored pathways for treatment of acute leukaemia. The compound has a strong rationale for use as a stratified medicine for adult, infant and paediatric indications which have a high unmet medical need. The drug development project encompasses preclinical validation of marker as...
